Franc Gay, MD, PhD, hematologist, Myeloma Un, Divisn of Hematology, Azienda Ospedaliero Universaria Ctà lla Salute e lla Scienza, discs the updated efficy data om the FORTE trial of patients wh newly-diagnosed multiple myeloma.
Contents:
- FRANC GAY, MD, ON THE FORTE TRIAL: TRIPLET THERAPY FOR NEWLY DIAGNOSED MULTIPLE MYELOMA
- DR. GAY DISCS THE EFFICY DATA OM THE FORTE TRIAL MYELOMA
FRANC GAY, MD, ON THE FORTE TRIAL: TRIPLET THERAPY FOR NEWLY DIAGNOSED MULTIPLE MYELOMA
* gay forte trial *
Gay et al. FigureDisclosurGay:Amgen: Honoraria, Membership on an enty's Board of Directors or advisory mte; Takeda: Honoraria, Membership on an enty's Board of Directors or advisory mte; Bristol-Myers Squibb: Honoraria, Membership on an enty's Board of Directors or advisory mte; Roche: Membership on an enty's Board of Directors or advisory mte; GSK: Membership on an enty's Board of Directors or advisory mte; AbbVie: Membership on an enty's Board of Directors or advisory mte; Adaptive: Membership on an enty's Board of Directors or advisory mte; Seattle Geics: Membership on an enty's Board of Directors or advisory mte; Onpeptis: Membership on an enty's Board of Directors or advisory mte; Janssen: Honoraria, Membership on an enty's Board of Directors or advisory mte; Celgene: Honoraria, Membership on an enty's Board of Directors or advisory mte.
DR. GAY DISCS THE EFFICY DATA OM THE FORTE TRIAL MYELOMA
Franc Gay, Universy of Toro, Toro, IT, prents a risk analysis update om the FORTE trial of rfilzomib + lenalidomi + xamethasone (KRd) wh, or whout, transplantatn * gay forte trial *
Updated rults om the FORTE trial were recently published Lancet Onlogy by Franc Gay et al.
Franc Gay talks about the Forte trial, a phase III clil trial for newly diagnosed multiple myeloma, at ASH 2018. * gay forte trial *
*Adapted om Gay, et al.
*Adapted om Gay et al. *Data om Gay, et al.
Dr Franc Gay speaks to encer about the survival analysis of newly diagnosed transplant-eligible multiple myeloma patients the randomised Forte trial * gay forte trial *
Gay F, Mto P, Rota-Slabri D, et al.
Gay F, Ma R, Rota-Slabriet D, al.